Claris Lifescience receives USFDA approval for Flumazenil injection

Claris Lifesciences has received USFDA approval for generic Flumazenil injection used for reversal of the sedative effects of benzodiazepines in the United States. The company has received drug approval Flumazenil injection USP 0.5 mg/5mL and 1 mg/10 mL multiple dose vials.

Company Profile : Claris Lifesciences Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.


*